Mode
Text Size
Log in / Sign up

Repetitive transcranial magnetic stimulation addresses various mental disorders including depression, bipolar disorder, and schizophreniaRepetitive Transcranial Magnetic Stimulation Shows Potential for Mental Disorders

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that rTMS shows potential for various mental disorders, though mechanistic data is primarily from preclinical research.

This narrative review synthesizes the therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) across several mental health conditions, including depression, bipolar disorder (BD), schizophrenia, attention deficit/hyperactivity disorder (ADHD), and autism spectrum disorder (ASD). The scope includes an assessment of brain functions and the underlying cellular and molecular mechanisms.

The review highlights that rTMS impacts neurotransmitter expression, neuroinflammation, neurotrophic factor production, oxidative stress, and gene expression related to brain plasticity and apoptosis. These findings regarding mechanism are primarily derived from preclinical research. Specific efficacy values for each individual disorder were not reported in the summary provided.

A noted limitation is that the synthesis of cellular and molecular mechanisms relies heavily on preclinical data rather than clinical trials. Clinical practice relevance involves the use of rTMS for mental disorders and its integration with neuroimaging to assess brain function. Because this is a narrative review, results should be interpreted as an overview of existing literature rather than primary evidence.

How this fits prior evidence

This narrative review addresses gaps in understanding the underlying mechanisms of rTMS by synthesizing preclinical data on neurotransmitter expression and neuroinflammation. It expands upon prior coverage regarding neuronavigation and connectivity guided targeting in rTMS to potentially improve outcomes in bipolar disorder. While previous findings established specific interventions like intranasal esketamine for treatment-resistant depression, this review provides a broader overview of the physiological mechanisms and therapeutic applications of rTMS across multiple psychiatric conditions.

This review looks at the use of repetitive transcranial magnetic stimulation (rTMS) to treat several mental health conditions. These include depression, bipolar disorder, schizophrenia, attention deficit/hyperactivity disorder (ADHD), and autism spectrum disorder (ASD). The review summarizes how this technology might help patients while also looking at how it affects brain functions.

One important part of the research focuses on what happens inside the brain at a cellular level. Because much of this specific data comes from preclinical studies, it is still early in the process. These studies look at things like neurotransmitter levels, inflammation, and how the brain creates new connections to help with healing.

While the review shows promise for these conditions, it is important to remember that many of the underlying mechanisms are based on lab research rather than direct human trials for every specific condition. Because this is a narrative review, it summarizes existing information rather than providing new clinical data. Talk to your doctor about how these treatments might fit into your personal care plan.

What this means for you:
rTMS shows potential for treating various mental disorders by influencing brain plasticity and cell health.

Common questions

What mental health conditions can rTMS treat?

The review discusses the use of rTMS for several conditions, including depression, bipolar disorder, schizophrenia, attention deficit/hyperactivity disorder (ADHD), and autism spectrum disorder (ASD). It explores how the treatment may impact brain function and plasticity for those living with these mental disorders.

How does rTMS work in the brain?

rTMS is thought to affect the brain by influencing several factors. These include neurotransmitter expression, neuroinflammation, and the production of neurotrophic factors. It also relates to how the brain manages oxidative stress and gene expression to promote neuroplasticity.

Is the research on rTMS fully proven for humans?

Much of the information regarding the specific cellular and molecular mechanisms of rTMS comes from preclinical research. Because this is a narrative review, it summarizes existing knowledge rather than providing new clinical trial results for every condition mentioned.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Over the past several decades, monoaminergic system dysfunction has been considered a key factor in the pathophysiology of some mental disorders. However, the therapeutic efficacy of drug therapy based on the monoamine hypothesis is unsatisfactory. In 2008, FDA approved the application of the repetitive transcranial magnetic stimulation (rTMS) for the treatment of patients with depression. Since then, TMS as a non-invasive neuromodulation technique, has been widely used to treat patients with mental disorders and assess their brain functions. This review article outlined the stimulation modes and parameter settings of TMS, summarized the therapeutic effects of TMS on main mental disorders such as depression, bipolar disorder (BD), schizophrenia, attention deficit/hyperactivity disorder (ADHD), and autism spectrum disorder (ASD), and synthesized the cellular and molecular mechanisms of its therapeutic effects for the mental disorders mainly based on preclinical research. These mechanisms involve pathophysiological processes such as neurotransmitter expression, neuroinflammation, neurotrophic factor production, oxidative stress, and gene expression related to brain plasticity and apoptosis in the brain. Furthermore, it introduced the emerging applications that combine TMS with other non-invasive neuroimaging techniques to assess brain function, including mapping neural pathways, measuring cortical excitability, and evaluating brain neuroplasticity. These advances have facilitated real-time evaluation of the therapeutic efficacy of TMS and optimized its application in treating mental disorders.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.